Dana-Farber Cancer Institute: Hematologic Neoplasms trials

The registry lists 16 Hematologic Neoplasms studies with Dana-Farber Cancer Institute as lead sponsor. 4 are open to participants now and 4 have results posted.

Phase 1 4Phase 2 5No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• HEME Home Transfusion ProgramRecruitingNCT06487247Not applicable
• Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)RecruitingNCT06469307Not applicable
• InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for CancerRecruitingNCT05463796
• Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeRecruitingNCT02269592
• Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic MalignanciesTerminatedNCT03717480Phase 2Results posted
• Patient-Centered Care for the Older Adult With Hematologic MalignancyCompletedNCT02359838Not applicableResults posted
• Rituximab for Prevention of Chronic GVHDCompletedNCT00379587Phase 1/2Results posted
• Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell TransplantationCompletedNCT00369226Phase 1/2Results posted
• MyeloGen: Germline Testing for Predisposition to Myeloid MalignanciesWithdrawnNCT06543511Not applicable
• Home Transfusion for HEMECompletedNCT05509439Not applicable
• Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic MalignanciesCompletedNCT00675831Phase 1
• Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic TransplantCompletedNCT00476177Phase 1
• Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell TransplantationCompletedNCT00355407Not applicable
• CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell TransplantationCompletedNCT00333190Not applicable
• Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell TransplantationCompletedNCT00146614Phase 2
• Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell TransplantationCompletedNCT00144703Phase 2